New Antibiotics: Can the Pipeline Meet Resistance

Why did COVID-19 expose the need for new antibiotics?

CDC reports that hospital-onset antimicrobial-resistant infections and associated deaths each increased by at least 15% between 2019 and 2020 across seven tracked pathogens. Hospitals cared for severely ill patients who needed longer stays and greater use of ventilators and catheters, while staffing shortages and disrupted prevention practices complicated infection control. These findings describe the pandemic's early impact, rather than infection rates in 2026. [CDC's COVID-19 and antimicrobial resistance review](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

The pharmaceutical concern extends beyond treating respiratory infections. Effective antibiotics support surgery, cancer treatment and organ transplantation by helping clinicians control bacterial complications. Resistance develops in microorganisms, not in a patient's body, and can leave fewer effective medicines available. Read together, CDC's findings and WHO's development assessment support a clear inference: hospitals need both stronger infection prevention and a dependable supply of effective treatments. [CDC's explanation of antimicrobial resistance](https://www.cdc.gov/antimicrobial-resistance/about/).

How many new antibacterial treatments are in development?

The total covers products at different stages of clinical development, including some approaching regulatory submission; it does not mean 90 medicines were ready for prescribing. WHO's assessment included candidates directed at priority bacteria, tuberculosis, Clostridioides difficile and Helicobacter pylori. Its clinical dashboard also cautions that some development programmes lack public trial registrations or timely disclosure of results, limiting independent assessment of their progress. [WHO's clinical antibacterial pipeline dashboard](https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens/).

Counting candidates is only part of evaluating the pipeline. WHO also examines whether traditional antibiotics introduce a different chemical class, attack a new bacterial target, work through a new mechanism or avoid known cross-resistance. Cross-resistance means that a bacterial defence against one medicine can also reduce susceptibility to another. These criteria help distinguish scientific novelty from a simple increase in product numbers, although meeting an innovation criterion does not itself establish superior clinical outcomes. [WHO's antibacterial development report](https://www.who.int/publications/i/item/9789240113091).

What would make a new antibiotic a meaningful treatment advance?

WHO's October 2025 update identified continuing shortages of oral treatment options and formulations suitable for children. It also reported that, from July 2017 through the review period, 17 antibacterial agents targeting priority bacterial pathogens obtained marketing authorization, but only two represented a new chemical class. The implication is that approval counts alone provide an incomplete picture: additional medicines can expand treatment choices without necessarily introducing fundamentally different ways to overcome resistance. [WHO's update on antibacterial treatment development](https://www.who.int/vanuatu/news/detail-global/02-10-2025-who-releases-new-reports-on-new-tests-and-treatments-in-development-for-bacterial-infections).

For readers assessing a treatment announcement, the distinction between laboratory activity, clinical testing and regulatory authorization matters. WHO's report evaluates expected usefulness and differences between candidates across clinical development phases; it is not a trial showing that every listed product benefits patients. A meaningful assessment therefore asks which infection was studied, whether resistant organisms were represented, what treatment served as the comparator and which safety findings emerged. An unfamiliar mechanism is promising, but the clinical evidence must establish where the medicine belongs in care. [WHO's development assessment and scope](https://www.who.int/publications/i/item/9789240113091).